Shares of Xencor Inc. (NASDAQ:XNCR) traded up 2.3% on Friday . The company traded as high as $18.46 and last traded at $18.38, with a volume of 300,128 shares. The stock had previously closed at $17.96.

XNCR has been the subject of a number of research reports. Oppenheimer Holdings Inc. reissued a “buy” rating on shares of Xencor in a research note on Monday, May 2nd. Leerink Swann reissued an “outperform” rating and issued a $18.00 price target on shares of Xencor in a research note on Wednesday, June 29th. Canaccord Genuity reissued a “buy” rating on shares of Xencor in a research note on Tuesday, June 28th. TheStreet raised shares of Xencor from a “sell” rating to a “hold” rating in a research note on Monday, April 25th. Finally, Zacks Investment Research raised shares of Xencor from a “hold” rating to a “buy” rating and set a $21.00 price target for the company in a research note on Tuesday, July 5th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $23.29.

The firm’s market capitalization is $748.89 million. The firm’s 50-day moving average price is $15.75 and its 200 day moving average price is $13.24.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings results on Monday, May 2nd. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.11. The company had revenue of $7.30 million for the quarter, compared to analyst estimates of $3.50 million. On average, analysts expect that Xencor Inc. will post ($0.77) EPS for the current fiscal year.

In other news, CEO Bassil I. Dahiyat sold 45,886 shares of the firm’s stock in a transaction that occurred on Tuesday, May 24th. The shares were sold at an average price of $13.00, for a total value of $596,518.00. Following the completion of the transaction, the chief executive officer now owns 358,186 shares of the company’s stock, valued at $4,656,418. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. Its segment is related to the development of pharmaceutical products. It uses its XmAb technology platform to create antibody product candidates designed to treat autoimmune and allergic diseases, cancer and other conditions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.